{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:32:25Z","timestamp":1790443945413,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tumor-induced osteomalacia (TIO) is an uncommon paraneoplastic syndrome presenting with sustained hypophosphatemia. Treatment of choice is removal of the tumor causing the TIO, but identification of the culprit tumor by routine imaging is challenging. This study aimed to assess the usefulness of somatostatin receptor imaging, called <jats:sup>68<\/jats:sup>Ga-DOTATOC PET\/CT, in the management of patients with TIO. Twelve patients who were suspected of having TIO underwent <jats:sup>68<\/jats:sup>Ga-DOTATOC PET\/CT. Lesion detectability and maximum standardized uptake value (SUV<jats:sub>max<\/jats:sub>) were determined and retrospectively compared with the clinical\/imaging surveillance and histopathologic diagnosis. The median duration of suspected TIO with hypophosphatemia was 7.8\u00a0years (range 2.1\u201321.0). Conventional radiologic and\/or nuclear medicine images failed to identify the culprit tumors. However, <jats:sup>68<\/jats:sup>Ga-DOTATOC PET\/CT scans showed that 8 of the 12 patients had positive lesions, suggesting the presence of focal culprit tumors. The SUV<jats:sub>max<\/jats:sub> of positive tumors was 1.9\u201345.7 (median: 11.5). Six skeletal lesions and two extra-skeletal lesions were identified. Seven of the lesions were pathologically confirmed as potential culprits of TIO. Hypophosphatemia was resolved in five patients who underwent lesion excision. The <jats:sup>68<\/jats:sup>Ga-DOTATOC PET\/CT is a useful whole-body imaging modality for the detection of causative tumors in patients with suspected TIO.<\/jats:p>","DOI":"10.1038\/s41598-021-81491-2","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T11:02:54Z","timestamp":1611054174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Usefulness of 68Ga-DOTATOC PET\/CT to localize the culprit tumor inducing osteomalacia"],"prefix":"10.1038","volume":"11","author":[{"given":"Dong Yun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom-Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pil Whan","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Jun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Min","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sook","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"key":"81491_CR1","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jama.294.10.1260","volume":"294","author":"JSM de Beur","year":"2005","unstructured":"de Beur, J. S. M. Tumor-induced osteomalacia. JAMA 294, 1260\u20131267 (2005).","journal-title":"JAMA"},{"key":"81491_CR2","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1097\/MPH.0000000000000686","volume":"39","author":"SS Crossen","year":"2017","unstructured":"Crossen, S. S. et al. Tumor-induced osteomalacia in a 3-year-old with unresectable central giant cell lesions. J. Pediatr. Hematol. Oncol. 39, e21\u2013e24 (2017).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"81491_CR3","doi-asserted-by":"publisher","first-page":"e1518","DOI":"10.1542\/peds.2014-2218","volume":"135","author":"E Fernandez-Cooke","year":"2015","unstructured":"Fernandez-Cooke, E. et al. Tumor-induced rickets in a child with a central giant cell granuloma: A case report. Pediatrics 135, e1518-1523 (2015).","journal-title":"Pediatrics"},{"key":"81491_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-020-00691-6","author":"P Florenzano","year":"2020","unstructured":"Florenzano, P. et al. Tumor-induced osteomalacia. Calcif. Tissue Int. https:\/\/doi.org\/10.1007\/s00223-020-00691-6 (2020).","journal-title":"Calcif. Tissue Int."},{"key":"81491_CR5","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/jbmr.1642","volume":"27","author":"Y Jiang","year":"2012","unstructured":"Jiang, Y. et al. Tumor-induced osteomalacia: An important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature. J. Bone Miner. Res. 27, 1967\u20131975 (2012).","journal-title":"J. Bone Miner. Res."},{"key":"81491_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jbmr.3903","volume":"35","author":"X Li","year":"2020","unstructured":"Li, X. et al. Nonremission and recurrent tumor-induced osteomalacia: A retrospective study. J. Bone Miner. Res. 35, 469\u2013477 (2020).","journal-title":"J. Bone Miner. Res."},{"key":"81491_CR7","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/jbmr.3219","volume":"32","author":"SH Tella","year":"2017","unstructured":"Tella, S. H. et al. Multimodality image-guided cryoablation for inoperable tumor-induced osteomalacia. J. Bone Miner. Res. 32, 2248\u20132256 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"81491_CR8","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1073\/pnas.101545198","volume":"98","author":"T Shimada","year":"2001","unstructured":"Shimada, T. et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. U.S.A. 98, 6500\u20136505 (2001).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"81491_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","volume":"28","author":"AL Folpe","year":"2004","unstructured":"Folpe, A. L. et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity\u2014An analysis of 32 cases and a comprehensive review of the literature. Am. J. Surg. Pathol. 28, 1\u201330 (2004).","journal-title":"Am. J. Surg. Pathol."},{"key":"81491_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.lpm.2010.10.011","volume":"40","author":"A Mekinian","year":"2011","unstructured":"Mekinian, A. et al. Curative surgical treatment after inefficient long-acting somatostatin analogues therapy of a tumor-induced osteomalacia. Presse Med. 40, 309\u2013313 (2011).","journal-title":"Presse Med."},{"key":"81491_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12891-015-0496-3","volume":"16","author":"ZJ Sun","year":"2015","unstructured":"Sun, Z. J., Jin, J., Qiu, G. X., Gao, P. & Liu, Y. Surgical treatment of tumor-induced osteomalacia: A retrospective review of 40 cases with extremity tumors. BMC Musculoskelet. Disord. 16, 43 (2015).","journal-title":"BMC Musculoskelet. Disord."},{"key":"81491_CR12","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1097\/RLU.0000000000000460","volume":"40","author":"K Agrawal","year":"2015","unstructured":"Agrawal, K. et al. Comparison of 18F-FDG and 68Ga DOTATATE PET\/CT in localization of tumor causing oncogenic osteomalacia. Clin. Nucl. Med. 40, e6\u2013e10 (2015).","journal-title":"Clin. Nucl. Med."},{"key":"81491_CR13","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1210\/jc.2016-2052","volume":"101","author":"D El-Maouche","year":"2016","unstructured":"El-Maouche, D. et al. (68)Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 101, 3575\u20133581 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"81491_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S8756-3282(99)00170-2","volume":"25","author":"S Fukumoto","year":"1999","unstructured":"Fukumoto, S., Takeuchi, Y., Nagano, A. & Fujita, T. Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone 25, 375\u2013377 (1999).","journal-title":"Bone"},{"key":"81491_CR15","first-page":"4970","volume":"15","author":"Z Shi","year":"2018","unstructured":"Shi, Z. et al. CT and MR imaging features in phosphaturic mesenchymal tumor-mixed connective tissue: A case report. Oncol. Lett. 15, 4970\u20134978 (2018).","journal-title":"Oncol. Lett."},{"key":"81491_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4103\/0972-3919.119541","volume":"28","author":"A Sood","year":"2013","unstructured":"Sood, A. et al. Bone scintigraphic patterns in patients of tumor induced osteomalacia. Indian J. Nucl. Med. 28, 173\u2013175 (2013).","journal-title":"Indian J. Nucl. Med."},{"key":"81491_CR17","first-page":"1922","volume":"56","author":"JC Reubi","year":"1996","unstructured":"Reubi, J. C., Waser, B., Laissue, J. A. & Gebbers, J. O. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: In vitro identification. Cancer Res. 56, 1922\u20131931 (1996).","journal-title":"Cancer Res."},{"key":"81491_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0140-6736(02)07846-7","volume":"359","author":"SMJ de Beur","year":"2002","unstructured":"de Beur, S. M. J. et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359, 761\u2013763 (2002).","journal-title":"Lancet"},{"key":"81491_CR19","doi-asserted-by":"publisher","first-page":"6088","DOI":"10.7150\/thno.30357","volume":"8","author":"RA Werner","year":"2018","unstructured":"Werner, R. A. et al. The theranostic promise for neuroendocrine tumors in the tlae 2010s\u2014Where do we stand, where do we go?. Theranostics 8, 6088\u20136100 (2018).","journal-title":"Theranostics"},{"key":"81491_CR20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s13139-018-0546-5","volume":"52","author":"S Ha","year":"2018","unstructured":"Ha, S. et al. Successful localization using (68)Ga-DOTATOC PET\/CT of a phosphaturic mesenchymal tumor causing osteomalacia in a patient with concurrent follicular lymphoma. Nucl. Med. Mol. Imaging 52, 462\u2013467 (2018).","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"81491_CR21","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1007\/s00259-008-0755-8","volume":"35","author":"C Von Falck","year":"2008","unstructured":"Von Falck, C. et al. Ga-68-DOTANOC PET\/CT for the detection of a mesenchymal tumor causing oncogenic osteomalacia. Eur. J. Nucl. Med. Mol. Imaging 35, 1034\u20131034 (2008).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"81491_CR22","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1007\/s00259-010-1512-3","volume":"37","author":"I Virgolini","year":"2010","unstructured":"Virgolini, I. et al. Procedure guidelines for PET\/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur. J. Nucl. Med. Mol. Imaging 37, 2004\u20132010 (2010).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"81491_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s10157-014-0962-5","volume":"19","author":"YA Hong","year":"2015","unstructured":"Hong, Y. A. et al. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease. Clin. Exp. Nephrol. 19, 208\u2013215 (2015).","journal-title":"Clin. Exp. Nephrol."},{"key":"81491_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.nucmedbio.2018.06.006","volume":"64\u201365","author":"E de Blois","year":"2018","unstructured":"de Blois, E., de Zanger, R. M. S., Oehlke, E., Chan, H. S. & Breeman, W. A. P. Semi-automated system for concentrating (68)Ga-eluate to obtain high molar and volume concentration of (68)Ga-Radiopharmaca for preclinical applications. Nucl. Med. Biol. 64\u201365, 16\u201321 (2018).","journal-title":"Nucl. Med. Biol."},{"key":"81491_CR25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/zaac.201600016","volume":"642","author":"M Pfeifer-Leeg","year":"2016","unstructured":"Pfeifer-Leeg, M. et al. Synthesis and characterization of Ga-III, Y-III, and Lu-III complexes with etifenin and analogues. Z. Anorg. Allg. Chem. 642, 486\u2013491 (2016).","journal-title":"Z. Anorg. Allg. Chem."},{"key":"81491_CR26","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1210\/jc.2011-1319","volume":"97","author":"EA Imel","year":"2012","unstructured":"Imel, E. A. & Econs, M. J. Approach to the hypophosphatemic patient. J. Clin. Endocrinol. Metab. 97, 696\u2013706 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"81491_CR27","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1007\/s00259-018-3971-x","volume":"45","author":"M Paquet","year":"2018","unstructured":"Paquet, M. et al. Diagnostic performance and impact on patient management of (68)Ga-DOTA-TOC PET\/CT for detecting osteomalacia-associated tumours. Eur. J. Nucl. Med. Mol. Imaging 45, 1710\u20131720 (2018).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"81491_CR28","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/RLU.0000000000000854","volume":"40","author":"JJ Zhang","year":"2015","unstructured":"Zhang, J. J. et al. 68Ga DOTATATE PET\/CT is an accurate imaging modality in the detection of culprit tumors causing osteomalacia. Clin. Nucl. Med. 40, 642\u2013646 (2015).","journal-title":"Clin. Nucl. Med."},{"key":"81491_CR29","first-page":"1072","volume":"90","author":"D Singh","year":"2017","unstructured":"Singh, D. et al. Oncogenic osteomalacia: Role of Ga-68 DOTANOC PET\/CT scan in identifying the culprit lesion and its management. Br. J. Radiol. 90, 1072 (2017).","journal-title":"Br. J. Radiol."},{"key":"81491_CR30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.clinimag.2019.04.007","volume":"56","author":"SJ Rayamajhi","year":"2019","unstructured":"Rayamajhi, S. J. et al. Tumor-induced osteomalacia\u2014Current imaging modalities and a systematic approach for tumor localization. Clin. Imaging 56, 114\u2013123 (2019).","journal-title":"Clin. Imaging"},{"key":"81491_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.crad.2007.05.017","volume":"63","author":"S Harish","year":"2008","unstructured":"Harish, S., Jurriaans, E., Jan, E., Sur, M. & Colterjohn, N. Giant cell tumour of soft tissue causing oncogenic osteomalacia: Report demonstrating the use of octreotide scintigraphy in tumour localization. Clin. Radiol. 63, 101\u2013107 (2008).","journal-title":"Clin. Radiol."},{"key":"81491_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s13139-018-0537-6","volume":"52","author":"HH Lee","year":"2018","unstructured":"Lee, H. H. et al. Recurrence of melanoma after initial treatment: Diagnostic performance of FDG PET in posttreatment surveillance. Nucl. Med. Mol. Imaging 52, 327\u2013333 (2018).","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"81491_CR33","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/RLU.0b013e318279eb13","volume":"38","author":"N Naswa","year":"2013","unstructured":"Naswa, N., Sharma, P., Kumar, R., Malhotra, A. & Bal, C. Successful localization of residual culprit tumor in a case of tumor-induced osteomalacia using Ga-68-DOTANOC PET\/CT. Clin. Nucl. Med. 38, 639\u2013640 (2013).","journal-title":"Clin. Nucl. Med."},{"key":"81491_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1014-8","author":"SS Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen, S. S. et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J. Rare Dis. https:\/\/doi.org\/10.1186\/s13023-019-1014-8 (2019).","journal-title":"Orphanet J. Rare Dis."},{"key":"81491_CR35","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1172\/JCI119809","volume":"100","author":"MJ Econs","year":"1997","unstructured":"Econs, M. J., McEnery, P. T., Lennon, F. & Speer, M. C. Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J. Clin. Investig. 100, 2653\u20132657 (1997).","journal-title":"J. Clin. Investig."},{"key":"81491_CR36","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00467-011-2086-4","volume":"27","author":"R Narazaki","year":"2012","unstructured":"Narazaki, R. et al. Linear nevus sebaceous syndrome with hypophosphatemic rickets with elevated FGF-23. Pediatr. Nephrol. 27, 861\u2013863 (2012).","journal-title":"Pediatr. Nephrol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81491-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81491-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81491-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T02:20:46Z","timestamp":1670034046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81491-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["81491"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-81491-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"assertion":[{"value":"7 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1819"}}